Sciencepulse

A Longer-Lasting Eye Treatment Aims to Ease the Injection Burden in Wet AMD

Health Tech·October 31, 2026

Wet age-related macular degeneration is one of the leading causes of vision loss in older adults. It happens when abnormal blood vessels grow beneath the macula, the central part of the retina, and leak fluid or blood. Over the past two decades, anti-VEGF drugs have become the standard of care. They block the vascular endothelial growth factor that drives this abnormal vessel growth, and many patients have kept useful sight because of them.

The drawback is the schedule. Anti-VEGF treatments are given as injections directly into the eye, and many patients need them on a repeating cycle. Each visit takes time, carries its own risks, and adds up for patients who must travel to appointments and for clinics that have to fit them in.

That is the problem a new candidate is meant to address. According to a podcast promoting the work, a longer-lasting treatment now in development aims to lengthen the gap between treatments while still helping preserve vision. The pitch is less about a new mechanism and more about reducing the number of visits without giving up on outcomes. The episode does not present the drug as approved, and the details of its trial results are not part of the material.

One note on the source: the podcast was produced for Ocular Therapeutix by Scientific American Custom Media, a unit that operates separately from the magazine's editorial board. This is sponsored content, not independent reporting. Readers who want to judge the claims should look to peer-reviewed trial data and regulatory filings before drawing conclusions.